Identification and validation of an immune-relevant risk signature predicting survival outcome and immune infiltration in uveal melanoma

Sun, Xiao; Li, Qingmin; Xu, Guijun

doi:10.1007/s10792-023-02869-x

Cited by 1 publication

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysregulation in immune pathways and HLA expression in high-risk UMs also contributes to an enhanced propensity for metastasis [ 171 ]. Patients with lower risk scores showed a higher infiltration proportion of CD8 + T-cells and a lower infiltration percentage of regulatory T-cells [ 228 ]. Macrophages M1 and M2 were two subtypes that play inverse functions.…”

Section: Immune Microenvironmentmentioning

confidence: 99%

“…Macrophages M1 and M2 were two subtypes that play inverse functions. Indeed, in low-risk patients, an elevated infiltration of M1 macrophages and a decrease in immunosuppressive M2 macrophages were observed [ 228 ]. Moreover, hypomethylation and increased expression of CD3D (CD3 delta subunit of T-cell receptor complex) promoted the infiltration of immune cells, as well as the proliferation, migration and invasion of UM cells, thereby accelerating the progression of UM [ 195 ].…”

Section: Immune Microenvironmentmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Molecular and Genetic Research on Uveal Melanoma

Fuentes-Rodriguez,

Mitchell,

Guérin

et al. 2024

Cells

View full text Add to dashboard Cite

Uveal melanoma (UM), a distinct subtype of melanoma, presents unique challenges in its clinical management due to its complex molecular landscape and tendency for liver metastasis. This review highlights recent advancements in understanding the molecular pathogenesis, genetic alterations, and immune microenvironment of UM, with a focus on pivotal genes, such as GNAQ/11, BAP1, and CYSLTR2, and delves into the distinctive genetic and chromosomal classifications of UM, emphasizing the role of mutations and chromosomal rearrangements in disease progression and metastatic risk. Novel diagnostic biomarkers, including circulating tumor cells, DNA and extracellular vesicles, are discussed, offering potential non-invasive approaches for early detection and monitoring. It also explores emerging prognostic markers and their implications for patient stratification and personalized treatment strategies. Therapeutic approaches, including histone deacetylase inhibitors, MAPK pathway inhibitors, and emerging trends and concepts like CAR T-cell therapy, are evaluated for their efficacy in UM treatment. This review identifies challenges in UM research, such as the limited treatment options for metastatic UM and the need for improved prognostic tools, and suggests future directions, including the discovery of novel therapeutic targets, immunotherapeutic strategies, and advanced drug delivery systems. The review concludes by emphasizing the importance of continued research and innovation in addressing the unique challenges of UM to improve patient outcomes and develop more effective treatment strategies.

show abstract

Section: Immune Microenvironmentmentioning

confidence: 99%

Section: Immune Microenvironmentmentioning

confidence: 99%